EXAS Exact Sciences Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXAS

Price (delayed)

$63.44

Market cap

$11.31B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.54

Enterprise value

$13.51B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
EXAS's revenue is up by 18% year-on-year and by 3.9% since the previous quarter
EXAS's gross profit is up by 15% year-on-year and by 3.5% since the previous quarter
The company's net income rose by 13% QoQ but it fell by 4.7% YoY
The company's quick ratio fell by 21% YoY and by 6% QoQ
The company's equity fell by 10% YoY and by 2.1% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.exactsciences.com/
Peers: MYGN VCYT BIOC

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
178.22M
Market cap
$11.31B
Enterprise value
$13.51B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.7
Price to sales (P/S)
5.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.48
Earnings
Revenue
$2.08B
EBIT
-$612.94M
EBITDA
-$386.74M
Free cash flow
-$413.02M
Per share
EPS
-$3.54
Free cash flow per share
-$2.34
Book value per share
$17.13
Revenue per share
$11.82
TBVPS
$10.91
Balance sheet
Total assets
$6.23B
Total liabilities
$3.18B
Debt
$2.45B
Equity
$3.04B
Working capital
$569.51M
Liquidity
Debt to equity
0.8
Current ratio
2.38
Quick ratio
1.91
Net debt/EBITDA
-5.7
Margins
EBITDA margin
-18.6%
Gross margin
72.4%
Net margin
-29.9%
Operating margin
-28.5%
Efficiency
Return on assets
-9.8%
Return on equity
-19.8%
Return on invested capital
-16.2%
Return on capital employed
-10.5%
Return on sales
-29.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
-4.1%
1 week
2.34%
1 month
-0.06%
1 year
-1.14%
YTD
28.14%
QTD
28.14%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$2.08B
Gross profit
$1.51B
Operating income
-$593.51M
Net income
-$623.51M
Gross margin
72.4%
Net margin
-29.9%
The operating margin has increased by 41% year-on-year and by 18% since the previous quarter
The operating income has increased by 31% year-on-year and by 15% since the previous quarter
EXAS's revenue is up by 18% year-on-year and by 3.9% since the previous quarter
The company's net margin rose by 16% QoQ and by 11% YoY

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.7
P/S
5.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.48
Exact Sciences's EPS has increased by 14% from the previous quarter
The stock's price to book (P/B) is 51% less than its 5-year quarterly average of 7.6 but 37% more than its last 4 quarters average of 2.7
The company's equity fell by 10% YoY and by 2.1% QoQ
EXAS's price to sales (P/S) is 58% less than its 5-year quarterly average of 12.9 but 25% more than its last 4 quarters average of 4.3
EXAS's revenue is up by 18% year-on-year and by 3.9% since the previous quarter

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has increased by 37% YoY and by 17% from the previous quarter
The company's return on invested capital rose by 29% YoY and by 13% QoQ
The ROE has contracted by 16% YoY but it has grown by 10% from the previous quarter
EXAS's return on assets is up by 12% since the previous quarter but it is down by 10% year-on-year

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 96% more than the total liabilities
The company's quick ratio fell by 21% YoY and by 6% QoQ
EXAS's current ratio is down by 14% YoY and by 3.6% QoQ
The company's debt is 20% lower than its equity
EXAS's debt to equity is up by 14% year-on-year
The company's equity fell by 10% YoY and by 2.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.